OMEGA THERAPEUTICS INC (OMGA)

US68217N1054 - Common Stock

3.65  +0.1 (+2.82%)

After market: 3.51 -0.14 (-3.84%)

Fundamental Rating

2

Overall OMGA gets a fundamental rating of 2 out of 10. We evaluated OMGA against 592 industry peers in the Biotechnology industry. Both the profitability and financial health of OMGA have multiple concerns. OMGA is valied quite expensively at the moment, while it does show a decent growth rate.



0

1. Profitability

1.1 Basic Checks

In the past year OMGA has reported negative net income.
OMGA had a negative operating cash flow in the past year.

1.2 Ratios

OMGA has a Return On Assets (-49.61%) which is comparable to the rest of the industry.
The Return On Equity of OMGA (-142.17%) is worse than 64.80% of its industry peers.
Industry RankSector Rank
ROA -49.61%
ROE -142.17%
ROIC N/A
ROA(3y)-68.14%
ROA(5y)N/A
ROE(3y)-136.25%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for OMGA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

3

2. Health

2.1 Basic Checks

OMGA does not have a ROIC to compare to the WACC, probably because it is not profitable.
OMGA has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, OMGA has a worse debt to assets ratio.

2.2 Solvency

OMGA has an Altman-Z score of -2.44. This is a bad value and indicates that OMGA is not financially healthy and even has some risk of bankruptcy.
OMGA's Altman-Z score of -2.44 is in line compared to the rest of the industry. OMGA outperforms 46.26% of its industry peers.
OMGA has a Debt/Equity ratio of 0.21. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.21, OMGA is not doing good in the industry: 69.05% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF N/A
Altman-Z -2.44
ROIC/WACCN/A
WACC8.96%

2.3 Liquidity

A Current Ratio of 3.80 indicates that OMGA has no problem at all paying its short term obligations.
OMGA has a Current ratio (3.80) which is in line with its industry peers.
A Quick Ratio of 3.80 indicates that OMGA has no problem at all paying its short term obligations.
OMGA's Quick ratio of 3.80 is in line compared to the rest of the industry. OMGA outperforms 43.54% of its industry peers.
Industry RankSector Rank
Current Ratio 3.8
Quick Ratio 3.8

4

3. Growth

3.1 Past

The earnings per share for OMGA have decreased by -7.22% in the last year.
Looking at the last year, OMGA shows a very strong growth in Revenue. The Revenue has grown by 111.11%.
EPS 1Y (TTM)-7.22%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q25.93%
Revenue 1Y (TTM)111.11%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2Q38.33%

3.2 Future

The Earnings Per Share is expected to grow by 7.81% on average over the next years.
OMGA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 80.14% yearly.
EPS Next Y10.54%
EPS Next 2Y8.41%
EPS Next 3Y8.58%
EPS Next 5Y7.81%
Revenue Next Year61.8%
Revenue Next 2Y46.54%
Revenue Next 3Y-25.99%
Revenue Next 5Y80.14%

3.3 Evolution

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for OMGA. In the last year negative earnings were reported.
Also next year OMGA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.41%
EPS Next 3Y8.58%

0

5. Dividend

5.1 Amount

No dividends for OMGA!.
Industry RankSector Rank
Dividend Yield N/A

OMEGA THERAPEUTICS INC

NASDAQ:OMGA (3/28/2024, 8:00:02 PM)

After market: 3.51 -0.14 (-3.84%)

3.65

+0.1 (+2.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap201.26M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -49.61%
ROE -142.17%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 3.8
Quick Ratio 3.8
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-7.22%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y10.54%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)111.11%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y